257 related articles for article (PubMed ID: 31568682)
1. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Bouchart C; Trépant AL; Hein M; Van Gestel D; Demetter P
Cancer Med; 2020 Feb; 9(3):1069-1078. PubMed ID: 31568682
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
4. Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma.
Behling F; Barrantes-Freer A; Behnes CL; Stockhammer F; Rohde V; Adel-Horowski A; Rodríguez-Villagra OA; Barboza MA; Brück W; Lehmann U; Stadelmann C; Hartmann C
PLoS One; 2020; 15(3):e0229274. PubMed ID: 32160197
[TBL] [Abstract][Full Text] [Related]
5. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
6. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib in glioblastoma recurrence: A case report.
Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
[TBL] [Abstract][Full Text] [Related]
11. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Buccarelli M; Marconi M; Pacioni S; De Pascalis I; D'Alessandris QG; Martini M; Ascione B; Malorni W; Larocca LM; Pallini R; Ricci-Vitiani L; Matarrese P
Cell Death Dis; 2018 Aug; 9(8):841. PubMed ID: 30082680
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Anselmo P; Maranzano E; Selimi A; Lupattelli M; Palumbo I; Bini V; Casale M; Trippa F; Bufi A; Arcidiacono F; Aristei C
Asia Pac J Clin Oncol; 2021 Jun; 17(3):273-279. PubMed ID: 33078909
[TBL] [Abstract][Full Text] [Related]
15. Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.
Trépant AL; Bouchart C; Rorive S; Sauvage S; Decaestecker C; Demetter P; Salmon I
Tumour Biol; 2015 Mar; 36(3):1943-53. PubMed ID: 25384509
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Oh J; Sahgal A; Sanghera P; Tsao MN; Davey P; Lam K; Symons S; Aviv R; Perry JR
Can J Neurol Sci; 2011 Jul; 38(4):621-5. PubMed ID: 21672702
[TBL] [Abstract][Full Text] [Related]
17. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M
Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906
[TBL] [Abstract][Full Text] [Related]
18. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
19. Management of glioblastoma: State of the art and future directions.
Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
